Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Standard

Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. / Harndahl, Mikkel Nors; Rasmussen, Michael; Roder, Gustav; Dalgaard Pedersen, Ida; Sørensen, Mikael; Nielsen, Morten; Buus, Søren.

In: European Journal of Immunology, Vol. 42, No. 6, 2012, p. 1405-1416.

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Harvard

Harndahl, MN, Rasmussen, M, Roder, G, Dalgaard Pedersen, I, Sørensen, M, Nielsen, M & Buus, S 2012, 'Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity' European Journal of Immunology, vol 42, no. 6, pp. 1405-1416., 10.1002/eji.201141774

APA

Harndahl, M. N., Rasmussen, M., Roder, G., Dalgaard Pedersen, I., Sørensen, M., Nielsen, M., & Buus, S. (2012). Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. European Journal of Immunology, 42(6), 1405-1416. 10.1002/eji.201141774

CBE

Harndahl MN, Rasmussen M, Roder G, Dalgaard Pedersen I, Sørensen M, Nielsen M, Buus S. 2012. Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. European Journal of Immunology. 42(6):1405-1416. Available from: 10.1002/eji.201141774

MLA

Vancouver

Harndahl MN, Rasmussen M, Roder G, Dalgaard Pedersen I, Sørensen M, Nielsen M et al. Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. European Journal of Immunology. 2012;42(6):1405-1416. Available from: 10.1002/eji.201141774

Author

Harndahl, Mikkel Nors; Rasmussen, Michael; Roder, Gustav; Dalgaard Pedersen, Ida; Sørensen, Mikael; Nielsen, Morten; Buus, Søren / Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity.

In: European Journal of Immunology, Vol. 42, No. 6, 2012, p. 1405-1416.

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Bibtex

@article{14d4f6bb0a054efd9c53203fa0798895,
title = "Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity",
publisher = "Wiley - V C H Verlag GmbH & Co. KGaA",
author = "Harndahl, {Mikkel Nors} and Michael Rasmussen and Gustav Roder and {Dalgaard Pedersen}, Ida and Mikael Sørensen and Morten Nielsen and Søren Buus",
year = "2012",
doi = "10.1002/eji.201141774",
volume = "42",
number = "6",
pages = "1405--1416",
journal = "European Journal of Immunology",
issn = "0014-2980",

}

RIS

TY - JOUR

T1 - Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity

A1 - Harndahl,Mikkel Nors

A1 - Rasmussen,Michael

A1 - Roder,Gustav

A1 - Dalgaard Pedersen,Ida

A1 - Sørensen,Mikael

A1 - Nielsen,Morten

A1 - Buus,Søren

AU - Harndahl,Mikkel Nors

AU - Rasmussen,Michael

AU - Roder,Gustav

AU - Dalgaard Pedersen,Ida

AU - Sørensen,Mikael

AU - Nielsen,Morten

AU - Buus,Søren

PB - Wiley - V C H Verlag GmbH & Co. KGaA

PY - 2012

Y1 - 2012

N2 - Efficient presentation of peptide‐MHC class I (pMHC‐I) complexes to immune T cells should benefit from a stable peptide‐MHC‐I interaction. However, it has been difficult to distinguish stability from other requirements for MHC‐I binding, for example, affinity. We have recently established a high‐throughput assay for pMHC‐I stability. Here, we have generated a large database containing stability measurements of pMHC‐I complexes, and re‐examined a previously reported unbiased analysis of the relative contributions of antigen processing and presentation in defining cytotoxic T lymphocyte (CTL) immunogenicity [Assarsson et al., J. Immunol. 2007. 178: 7890–7901]. Using an affinity‐balanced approach, we demonstrated that immunogenic peptides tend to be more stably bound to MHC‐I molecules compared with nonimmunogenic peptides. We also developed a bioinformatics method to predict pMHC‐I stability, which suggested that 30% of the nonimmunogenic binders hitherto classified as “holes in the T‐cell repertoire” can be explained as being unstably bound to MHC‐I. Finally, we suggest that nonoptimal anchor residues in position 2 of the peptide are particularly prone to cause unstable interactions with MHC‐I. We conclude that the availability of accurate predictors of pMHC‐I stability might be helpful in the elucidation of MHC‐I restricted antigen presentation, and might be instrumental in future search strategies for MHC‐I epitopes.

AB - Efficient presentation of peptide‐MHC class I (pMHC‐I) complexes to immune T cells should benefit from a stable peptide‐MHC‐I interaction. However, it has been difficult to distinguish stability from other requirements for MHC‐I binding, for example, affinity. We have recently established a high‐throughput assay for pMHC‐I stability. Here, we have generated a large database containing stability measurements of pMHC‐I complexes, and re‐examined a previously reported unbiased analysis of the relative contributions of antigen processing and presentation in defining cytotoxic T lymphocyte (CTL) immunogenicity [Assarsson et al., J. Immunol. 2007. 178: 7890–7901]. Using an affinity‐balanced approach, we demonstrated that immunogenic peptides tend to be more stably bound to MHC‐I molecules compared with nonimmunogenic peptides. We also developed a bioinformatics method to predict pMHC‐I stability, which suggested that 30% of the nonimmunogenic binders hitherto classified as “holes in the T‐cell repertoire” can be explained as being unstably bound to MHC‐I. Finally, we suggest that nonoptimal anchor residues in position 2 of the peptide are particularly prone to cause unstable interactions with MHC‐I. We conclude that the availability of accurate predictors of pMHC‐I stability might be helpful in the elucidation of MHC‐I restricted antigen presentation, and might be instrumental in future search strategies for MHC‐I epitopes.

U2 - 10.1002/eji.201141774

DO - 10.1002/eji.201141774

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 6

VL - 42

SP - 1405

EP - 1416

ER -